TRISALUS LIFE SCIENCES INC (TLSI) Stock Price, Quote, News and Overview
NASDAQ:TLSI - Nasdaq - US89680M1018 - Common Stock - Currency: USD
TLSI Quote, Performance and Key Statistics
3.67
-0.28 (-7.09%)
The current stock price of TLSI is 3.67 USD. In the past month the price decreased by -26.6%. In the past year, price decreased by -35.16%.
TLSI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.78 | 351.27B | ||
| AMGN | AMGEN INC | 13.05 | 153.09B | ||
| GILD | GILEAD SCIENCES INC | 14.25 | 137.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.17 | 96.46B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.27 | 60.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 56.73B | ||
| ARGX | ARGENX SE - ADR | 72.53 | 41.15B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.66 | 32.28B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.77B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.85B | ||
| INSM | INSMED INC | N/A | 20.74B | ||
| NTRA | NATERA INC | N/A | 19.26B |
Related stock screener links
About TLSI
Company Profile
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company is headquartered in Westminster, Colorado and currently employs 110 full-time employees. The company went IPO on 2020-12-18. The firm is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
Company Info
TRISALUS LIFE SCIENCES INC
6272 W. 91st Ave.
Westminster COLORADO US
Employees: 110
Phone: 14153368917
TRISALUS LIFE SCIENCES INC / TLSI FAQ
What is the stock price of TRISALUS LIFE SCIENCES INC today?
The current stock price of TLSI is 3.67 USD. The price decreased by -7.09% in the last trading session.
What is the ticker symbol for TRISALUS LIFE SCIENCES INC stock?
The exchange symbol of TRISALUS LIFE SCIENCES INC is TLSI and it is listed on the Nasdaq exchange.
On which exchange is TLSI stock listed?
TLSI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TRISALUS LIFE SCIENCES INC stock?
14 analysts have analysed TLSI and the average price target is 11.54 USD. This implies a price increase of 214.41% is expected in the next year compared to the current price of 3.67. Check the TRISALUS LIFE SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TRISALUS LIFE SCIENCES INC worth?
TRISALUS LIFE SCIENCES INC (TLSI) has a market capitalization of 138.87M USD. This makes TLSI a Micro Cap stock.
How many employees does TRISALUS LIFE SCIENCES INC have?
TRISALUS LIFE SCIENCES INC (TLSI) currently has 110 employees.
What are the support and resistance levels for TRISALUS LIFE SCIENCES INC (TLSI) stock?
TRISALUS LIFE SCIENCES INC (TLSI) has a resistance level at 5.07. Check the full technical report for a detailed analysis of TLSI support and resistance levels.
Is TRISALUS LIFE SCIENCES INC (TLSI) expected to grow?
The Revenue of TRISALUS LIFE SCIENCES INC (TLSI) is expected to grow by 53.18% in the next year. Check the estimates tab for more information on the TLSI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TRISALUS LIFE SCIENCES INC (TLSI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TLSI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TLSI, evaluating the profitability, health, valuation and growth aspects
- TRISALUS LIFE SCIENCES INC (TLSI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TRISALUS LIFE SCIENCES INC (TLSI) Sales and EPS estimates to see what analysts future expectations are.
- TRISALUS LIFE SCIENCES INC (TLSI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TRISALUS LIFE SCIENCES INC (TLSI) Insider and Institutional Ownership to learn about the owners and their transactions.
- TRISALUS LIFE SCIENCES INC (TLSI) Stock Chart to make your own analysis
- TRISALUS LIFE SCIENCES INC (TLSI) Latest news and press-releases to stay up to date.
Does TRISALUS LIFE SCIENCES INC (TLSI) stock pay dividends?
TLSI does not pay a dividend.
When does TRISALUS LIFE SCIENCES INC (TLSI) report earnings?
TRISALUS LIFE SCIENCES INC (TLSI) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of TRISALUS LIFE SCIENCES INC (TLSI)?
TRISALUS LIFE SCIENCES INC (TLSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.12).
What is the Short Interest ratio of TRISALUS LIFE SCIENCES INC (TLSI) stock?
The outstanding short interest for TRISALUS LIFE SCIENCES INC (TLSI) is 3.24% of its float. Check the ownership tab for more information on the TLSI short interest.
TLSI Technical Analysis
TLSI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TLSI. TLSI has a bad profitability rating. Also its financial health evaluation is rather negative.
TLSI Financial Highlights
Over the last trailing twelve months TLSI reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 20.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.83% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TLSI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TLSI. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 35.14% and a revenue growth 53.18% for TLSI